-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Upgrades ACADIA Pharmaceuticals to Buy, Maintains Price Target to $29

Benzinga·03/25/2026 12:46:08
Listen to the news
B of A Securities analyst Tazeen Ahmad upgrades ACADIA Pharmaceuticals (NASDAQ:ACAD) from Neutral to Buy and maintains the price target from $29 to $29.